Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.

Clinical chemistry - 1 Jul 2004

Irving Julie A E, O'Brien Stephen, Lennard Anne L, Minto Lynne, Lin Feng, Hall Andrew G

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fusion Proteins, bcr-abl
Share to Genes, abl
Share to Imatinib Mesylate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Piperazines

Share to Protein-Tyrosine Kinases

Share to Pyrimidines

Source

Identifiers

PMID: 15229152
DOI: 10.1373/clinchem.2004.034801

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.PMID 15229152Read ↗

Denaturing-HPLC-Based Assay for Detection of ABL Mutations in Chronic Myeloid Leukemia Patients Resistant to ImatinibSemantic proximity Read ↗

Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatographySemantic proximity Read ↗

Double-gradient-denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients.Semantic proximity Read ↗

New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.Semantic proximity Read ↗

Detection of BCR-ABL mutations and resistance to imatinib mesylate.Semantic proximity Read ↗

Denaturing HPLC-based assay for molecular screening of nondeletional mutations causing alpha-thalassemias.Semantic proximity Read ↗

Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC.Semantic proximity Read ↗

High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain.Semantic proximity Read ↗

A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.Semantic proximity Read ↗

Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients.Semantic proximity Read ↗

Rapid detection of Flt3 mutations in acute myeloid leukemia patients by denaturing HPLC.Semantic proximity Read ↗

Use of denaturing HPLC to provide efficient detection of mutations causing guanidinoacetate methyltransferase deficiency.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.